Anti-Müllerian Hormone Testing Market: By Product Type (POC Testing, Self-check kits), By End-User (Hospitals, Diagnostic Centers, Fertility Clinics, Research Laboratories, Others), By Application (Fertility Assessment, PCOS Diagnosis, Ovarian Function Evaluation, Menopause Prediction, Others), and Geography

Anti-Müllerian Hormone Testing Market size was valued at USD 256.3 million in 2023 and is poised to grow at a 5.9% CAGR from 2024 to 2030. Anti-Müllerian hormone is produced by granulosa cells in ovarian follicles, serves as a reliable biomarker for ovarian function, and is widely used in fertility clinics and reproductive health centers. The anti-müllerian hormone testing market is experiencing significant growth due to the rising prevalence of infertility and reproductive disorders worldwide. Anti-müllerian hormone testing has emerged as a crucial tool in assessing ovarian reserve and predicting reproductive potential in women. The global anti-müllerian hormone testing market is driven by several factors, including the increasing incidence of polycystic ovary syndrome (PCOS), growing awareness about fertility preservation, and the rising average age of first-time mothers. According to recent statistics, PCOS affects approximately 8-13% of women of reproductive age globally, with rates varying across different populations. This prevalence has led to a surge in demand for anti-müllerian hormone testing as a diagnostic tool for PCOS and other reproductive disorders. Furthermore, the expanding field of assisted reproductive technologies (ART) has significantly contributed to market growth. In vitro fertilization (IVF) procedures have seen a steady increase. Since the pioneering success of IVF in 1978, the worldwide application of this reproductive technology has grown exponentially. In the four decades following that groundbreaking event, IVF has revolutionized fertility treatment, leading to the birth of approximately 8 million children globally through assisted pregnancies.

Anti-müllerian hormone testing plays a critical role in predicting ovarian response to stimulation in IVF treatments, making it an essential component of fertility assessments. The anti-müllerian hormone testing market is also benefiting from technological advancements in testing methods, with the development of more sensitive and automated assays. These innovations have improved the accuracy and reliability of anti-müllerian hormone measurements, further driving adoption in clinical settings. However, the market faces challenges such as limited reimbursement policies for anti-müllerian hormone testing in some regions and the potential for inconsistent results across different testing platforms. Despite these obstacles, the increasing focus on personalized medicine and the growing demand for non-invasive diagnostic tools are expected to propel the anti-müllerian hormone testing market forward. As research continues to uncover new applications for anti-müllerian hormone testing, including its potential role in predicting menopause onset and assessing certain ovarian cancers, the market is poised for continued expansion in the forecasted years.

Anti Müllerian Hormone Testing Market Key Developments:

• In June 2021, Beckman Coulter introduced an Access AMH Advanced assay with a validated cut-off to assess ovarian response, aiding clinicians in predicting poor outcomes for patients undergoing IVF-related controlled ovarian stimulation.